drugset / Trial / NCT07601295
Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
Phase 2
Not yet recruiting
90 enrolled
Stanford University
National Heart, Lung, and Blood Institute (NHLBI) · collabUniversity of Michigan · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The primary objective of this study is to compare the efficacy, safety, and tolerability of tiprelestat plus Standard of Care (SOC) compared with placebo plus SOC in patients with World Health Organization (WHO) functional class II-IV pulmonary arterial hypertension (PAH).
Timeline
- Start
- 2026-07
- Primary completion
- 2030-02
- Completion
- 2030-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tiprelestat | Unknown | 5 mg | Subcutaneous |
| Subject | Tiprelestat | Unknown | 10 mg | Subcutaneous |